Biovica International AB Class B AI Stock Analysis
Biovica International AB Class B (9II) AI Stock Analysis
Biovica International AB Class B
(Frankfurt:9II)
No summary available
Biovica International AB Class B (9II) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 7.72M
- Dividend Yield
- ―
- Average Volume (3M)
- 20.00K
- Price to Earnings (P/E)
- -1.2
- Beta (1Y)
- 8.64
- Revenue Growth
- 61.35%
- EPS Growth
- 62.60%
- Country
- Germany
- Employees
- 24
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Biovica International AB Class B Business Overview & Revenue Model
Company Description
Biovica International AB (publ) operates as a biotechnology enterprise, concentrating on the development and market introduction of sophisticated blood-based biomarker tests. These diagnostic solutions aim to enhance the tracking and prediction of ca...
Biovica International AB Class B Peers Comparison
Overall Rating
SE:CANTA83Outperform
SE:SPRINT80Outperform
SE:FLUI70Outperform
SE:ELIC48Neutral
SE:SPAGO42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 83Outperform | SEK 360.89M | 1.90 | 63.09% | ― | ― | ― | |
| 80Outperform | SEK 400.96M | 5.49 | 71.44% | ― | 170.38% | ― | |
| 70Outperform | SEK 29.81M | 5.84 | 34.47% | ― | 630.57% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | SEK 162.84M | -6.97 | -56.09% | ― | ― | 14.10% | |
| 42Neutral | SEK 33.21M | -1.03 | -87.37% | ― | -97.52% | 31.31% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:9II | Biovica International AB Class B | 0.02 | -0.00 | -11.11% | |
| SE:ELIC | Elicera Therapeutics AB | 2.46 | -2.70 | -52.27% | |
| SE:SPAGO | Spago Nanomedical AB | 0.04 | -0.05 | -56.84% | |
| SE:CANTA | Cantargia AB | 1.29 | -1.94 | -60.03% | |
| SE:SPRINT | Sprint Bioscience AB | 3.68 | 2.24 | 155.56% | |
| SE:FLUI | Fluicell AB | 21.10 | 10.30 | 95.37% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
